Coupling of mutated met variants to DNA repair via Abl and Rad51

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5769-5777

  Ganapathipillai, Suganthini S ^a   Medová, Michaela ^a   Aebersold, Daniel M ^a   Manley, Paul W ^c   Berthou, Sylvie ^a   Streit, Bruno ^a   Blank Liss, Wieslawa ^a   Greiner, Richard H ^a   Rothen Rutishauser, Barbara ^b   Zimmer, Yitzhak ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NILOTINIB; RAD51 PROTEIN; SCATTER FACTOR RECEPTOR; ((3Z) N (3 CHLOROPHENYL) 3 ((3,5 DIMETHYL 4 ((4 METHYLPIPERAZIN 1 YL)CARBONYL) 1H PYRROL 2 YL)METHYLENE) N METHYL 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONAMIDE); ((3Z)-N-(3-CHLOROPHENYL)-3-((3,5-DIMETHYL-4-((4-METHYLPIPERAZIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-N-METHYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE); BENZOTHIAZOLE DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; PIFITHRIN; PIPERAZINE DERIVATIVE; RADIOSENSITIZING AGENT; SULFONAMIDE; TOLUENE; TYROSINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG INHIBITION; GENE MUTATION; GENE TRANSLOCATION; GENETIC VARIABILITY; NONHUMAN; PRIORITY JOURNAL; ACTIVE TRANSPORT; ANIMAL; CELL STRAIN 3T3; CHEMISTRY; DNA DAMAGE; GENETICS; METABOLISM; MOUSE; MUTATION; ONCOGENE; PHOSPHORYLATION; PHYSIOLOGY;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BENZOTHIAZOLES; DNA DAMAGE; DNA REPAIR; GENES, ABL; INDOLES; MICE; MUTATION; NIH 3T3 CELLS; PHOSPHORYLATION; PIPERAZINES; RAD51 RECOMBINASE; RADIATION-SENSITIZING AGENTS; SULFONAMIDES; TOLUENE; TYROSINE; VARIATION (GENETICS);

EID: 48649092035     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1269     Document Type: Article

References (24)

1. Bardelli A, Longati P, Gramaglia D, et al. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci U S A 1998;95:14379-83.
2. Daboussi F, Dumay A, Delacote F, Lopez BS. DNA double-strand break repair signalling: the case of RAD51 post-translational regulation. Cell Signal 2002;14:969-75.
3. Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002;21:8591-604.
4. Chen G, Yuan SS, Liu W, et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 1999;274:12748-52.
5. Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001;8:795-806.
6. Takizawa Y, Kinebuchi T, Kagawa W, Yokoyama S, Shibata T, Kurumizaka H. Mutational analyses of the human Rad51-315 residue, a site for phosphorylation in leukaemia cells. Genes Cells 2004;9:781-90.
7. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387-93.
8. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-54.
9. Aebersold DM, Kollar A, Beer KT, Laissue J, Greiner RH, Djonov V. Involvement of the hepatocyte growth factor/ scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 2001;96:41-54.
10. Aebersold DM, Landt O, Berthou S, et al. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 2003;22:8519-23.
11. Fan S, Wang JA, Yuan RQ, et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 1998;17:131-41.
12. Lowndes NF, Toh GW. DNA repair: the importance of phosphorylating histone H2AX. Curr Biol 2005;15:R99-102.
13. Taneja N, Davis M, Choy JS, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 2004;279:2273-80.
14. Boulaire J, Fotedar A, Fotedar R. The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris) 2000;48:190-202.
15. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1773-7.
16. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004;266:37-56.
17. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005;10:1881-96.
18. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6:61-73.
19. Lal B, Xia S, Abounader R, Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 2005;11:4479-86.
20. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
21. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003;22:660-4.
22. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-9.
23. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
24. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41.